About Relief TherapeuticsRelief Therapeutics aims to become a key player in the biotechnology and pharmaceutical industry.
We will provide patients with therapeutic relief from diseases for which high needs persist.
We strongly believe that only by effectively treating patients will our investors realize significant return on investment.
Our areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets.
Our experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential.
Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decisive results.
CEO: Raffaele Petrone
CFO: Tim Snyder
COO: Gael Hedou
CSO: Yves Sagot
Chief Business Officer: Michel Dreano
Chief Development Officer: Dorian Bevec
26 articles with Relief Therapeutics
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) has been reported under FDA Emergency Use IND authorization at multiple clinical sites
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites
FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19: Currently in development by NeuroRx and Relief Therapeutics under Fast Track Designation
Expanded access is available to patients who are ineligible for enrollment in the FDA clinical trial of RLF-100, including pregnant women
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holdings AG announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track FDA trials of RLF-100 in patients with Critical COVID-19 with respiratory failure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
6/15/2020It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital
RELIEF THERAPEUTICS Holding AG “Relief” and its U.S. partner, NeuroRx, Inc. announced that Houston Methodist Hospital is participating in their Phase 2 clinical trial evaluating RLF-100 as a research intervention for critically ill patients with COVID-19 and respiratory failure.
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure
RELIEF THERAPEUTICS Holding AG “Relief” and its U.S. partner, NeuroRx, Inc. announced that the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with respiratory failure has been expanded to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators.
6/8/2020As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100
5/18/2020Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilation
Relief Therapeutics Announces Filing of IND for Phase 2/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury
Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU care
Relief Therapeutics Holding (RLF:SIX) Drug Aviptadil Enters FDA Trial at NYU Langone Health, New York, to Treat COVID-19-Induced Acute Respiratory Distress
Aviptadil targets the cytokine storm that causes fatal Respiratory Distress in COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to Treat COVID-19-induced Acute Respiratory Distress
RELIEF THERAPEUTICS Holding AG “Relief” announces that its drug Aviptadil has now entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia for the treatment of Acute Respiratory Distress Syndrome in COVID-19.
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
Aviptadil is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS - Coronavirus (COVID-19) death is primarily caused by Acute Respiratory Distress Syndrome (ARDS), in which severe inflammation causes the lungs to fill with fluid and even mechanical ventilation is unable to maintain life. The syndrome is caused by a Cytokine Storm unleashed by viral particles. - VIP is known to have potent anti-cytokine effects in nu